David Risinger, an analyst from Leerink Partners, has initiated a new Buy rating on Metsera, Inc. (MTSR).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that highlight Metsera, Inc.’s potential in the obesity treatment market. The company’s innovative platform and pipeline of peptide-based therapeutics are seen as having significant advantages over competitors. These include a monthly injectable GLP-1 and amylin, a daily oral GLP-1 peptide, and cost-effective peptide manufacturing capabilities.
Risinger emphasizes the experienced leadership team at Metsera, Inc., which includes executives with strong track records. The company’s most advanced candidate, MET-097i, is projected to achieve over $5 billion in peak sales, with ongoing clinical trials expected to yield preliminary data by September 2025. These factors collectively underpin the confidence in Metsera’s ability to outperform in the market.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Amgen. According to TipRanks, Risinger has an average return of 10.0% and a 55.89% success rate on recommended stocks.
In another report released on August 28, Bank of America Securities also maintained a Buy rating on the stock with a $50.00 price target.